drugset / Trial / NCT04396886
Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC
Phase 2
Completed
38 enrolled
The University of Hong Kong
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · collab
NaSingle-groupOpen-labelTreatment
Summary
This would be a phase II prospective single arm mono-institutional study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of bintrafusp alfa in previously treated patients with recurrent and metastatic (R/M) non-keratinizing nasopharyngeal carcinoma (NPC).
Timeline
- Start
- 2020-02-27
- Primary completion
- 2022-09-30
- Completion
- 2023-07-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bintrafusp alfa | Protein / enzyme biologic | — | Intravenous |